Explore UAB

Required for MOC- Complete by February 17, 2022.

David Kimberlin, MD, FAAP, Professor of Pediatrics, University of Alabama at Birmingham

Speaker Disclosure

David Kimberlin, MD, FAAP

  • Does intend to discuss commercial products or services

  • Will discuss non-FDA approved uses of products/providers of services

  • Discloses a relationship with Gilead as the principal investigator for a pediatric remdesivir study.

  • All monies go directly to UAB 

Introduction

This module was recorded in August 2021 and reflects the evidence known at that time around COVID-19. Immunization is a cornerstone of public health policy and is demonstrably highly cost-effective when used to protect child health.  This module examines the various vaccine platforms that are authorized or in development for COVID vaccines. The module provides an introductory overview of the COVID vaccine and assess the safety of currently authorized COVID vaccines for the pediatric population through examining the present data on the efficacy/effectiveness of COVID vaccines.

Learning Objectives

Upon completion of this internet enduring material activity, participants will be able to:

  • Discuss the vaccine platforms that are authorized/approved or in development for COVID vaccines.

  • Assess the safety of currently authorized COVID vaccines.

  • Present data on the efficacy/effectiveness of COVID vaccines

Please review the information below and follow the instructions to view the training, complete the online evaluation form, and successfully pass the online post-test, which will automatically submit for CME credit(s).

Commercial Support

This activity does not receive funding from any ineligible company. An ineligible company is any entity producing, marketing, selling, re-selling or distributing healthcare goods or services consumed by, or used on, patients.

 

Disclaimer Statement

This Internet Enduring Material activity does not necessarily reflect the views, opinions, policies or procedures of the Alabama Chapter-American Academy of Pediatrics, Children’s of Alabama, or its staff or representatives.  Alabama Child Health Improvement Alliance cannot and does not assume any responsibility for the use, misuse or misapplication of any information. 

Designation Statement

Children of Alabama designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of the State of Alabama through the joint providership of Children's of Alabama and the Alabama Child Health Improvement Alliance.  Children's of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.

Enduring Materials Information

Formats Available: Streaming*
On-Demand Release Date: 11/16/2021

On-Demand Expiration Date: 11/16/2022

Please note that effective July 1, 2011, enduring materials are required to provide an assessment of the learner that measures achievement of the educational purpose and/or objectives of the activity.  Upon completion of this activity, you will be directed to the post-test.  To receive your CME certificate, you must score a minimum of 75% on the test.

Instructions

All three steps are required: 

1. Video Training

David Kimberlin, MD, FAAP, Professor of Pediatrics, University of Alabama at Birmingham “Vaccine Basics for COVID” Required for MOC (Video Time: 44 min)

Click HERE to access the video.  It is recommended that you access the PowerPoint presentation handout HERE to review as you watch the video.  You will be instructed to return here to access the post-test and CME activity evaluation.

2. Post-Test

For Non-Physician:To take test, non-physician posttest. You must click through and complete entire test (75% pass rate) for your test results to be submitted for CME credit AND certification.On the last screen you will see your test score and if passing you will be sent a CME certificate from Linda Champion.

For MD:To take test, choose physician post-test. You must click through and complete entire test (75% pass rate) for your test results to be submitted for MOC PArt 2 credit AND certification.

Credit Assignment Criteria: Upon completion of the activity and successfully passing the post test, you will be sent a MOC Part 2 Claim form to complete and return back to Linda Champion at lchampion@alaap.org. On this form you will be required to enter your American Board of Pediatrics (ABP) Diplomate number*) and date of birth (MM/DD). Your ABP Diplomate number can be found in your ABP online profile. If you are unable to locate this number, you may look it up by clicking here or please contact the American Board of Pediatrics [Telephone: (919) 929-0461, Business Hours: (8:30 am – 5:00 pm ET Monday – Friday), E-mail: abpeds@abpeds.org].

*Please note that your American Academy of Pediatrics member ID number is not accepted for MOC Part 2 credit reporting.

Your credit will be entered into the ACCME’s Program and Activity Reporting System (PARS), this system will transfer your credit into your ABP profile. 

Within 30 days after you finish a MOC Part 2 activity that is approved for ABP’s MOC Part 2 credit, your Part 2 points will appear automatically in your ABP Portfolio, MOC Part 2 credit. CME providers are responsible for reporting your completion to the ABP within 30 days. You do not have to send separate documentation to the ABP. 

3. Evaluation

Click HERE to take/submit CME activity evaluation.

Vaccine Basics for COVID Bibliography

CDC MMWR July 30, 2021, Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w

Khoury, D.S., Cromer, D., Reynaldi, A. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205–1211 (2021). https://doi.org/10.1038/s41591-021-01377-8

Pollard, A.J., Bijker, E.M. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21, 83–100 (2021). https://doi.org/10.1038/s41577-020-00479-7

Jamie Lopez Bernal, F.F.P.H., Ph.D., Nick Andrews, Ph.D., Charlotte Gower, D.Phil., Eileen Gallagher, Ph.D., Ruth Simmons, Ph.D., Simon Thelwall, Ph.D., Julia Stowe, Ph.D., Elise Tessier, M.Sc., Natalie Groves, M.Sc., Gavin Dabrera, M.B., B.S., F.F.P.H., Richard Myers, Ph.D., Colin N.J. Campbell, M.P.H., F.F.P.H., et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England Journal of Medicine, July 21, 2021. https://www.nejm.org/doi/full/10.1056/nejmoa2108891